Navigation Links
Forest Laboratories' Lexapro and Generics-Dominated Fluoxetine Lead First-Line Therapy in the Treatment for Major Depression
Date:10/2/2007

Doctors Disagree Over Which Drugs Are More Effective, According to a New

Report from Decision Resources

WALTHAM, Mass., Oct. 1 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Forest Laboratories' Lexapro and generics- dominated fluoxetine lead first-line therapy in the treatment of major depression. According to the new report entitled Treatment Algorithms in Major Depression, selective serotonin reuptake inhibitors (SSRIs), which include Lexapro and Prozac, account for 63.6 percent of patients on first-line therapy. Surveyed physicians indicate the reasons for SSRIs being so heavily used are efficacy, cost and physician familiarity. Eighty percent of surveyed psychiatrists and seventy percent of surveyed primary-care physicians (PCPs) said the reason why they chose SSRIs over benzodiazepines is efficacy. The major reason 49 percent of surveyed psychiatrists chose SSRIs over serotonin/norepinephrine reuptake inhibitors (SNRIs) is cost, while 49 percent of PCPs say they chose SSRIs over SNRIs owing to familiarity with the former class.

The report also finds that psychiatrists and PCPs do not all agree on what the most effective drugs are for treatment of major depression; therefore there is significant variation in the choice of agents, with no clear dominant player. Forty four percent of surveyed PCPs say SSRIs are more effective than SNRIs, but 72 percent of psychiatrists believe the opposite. Sixty two percent of surveyed PCPs think Lexapro's efficacy against depression is a major reason to choose it, but only 24 percent of surveyed psychiatrists agree.

"We project a significant increase in the use of SNRIs in first-line therapy in the next two years," said Michael Malecki, Ph.D., analyst at Decision Resources. "Forty five percent of surveyed psychiatrists and forty eight percent of surveyed PCPs say they will more frequently prescribe SNRIs in first line. We believe that generic forms of Wyeth's Effexor XR will help make SNRIs more cost effective, thus driving the use of this class in early therapy."

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics(R) to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

For each disease examined, Decision Resources' Treatment Algorithms Insight Series provides:

-- Summary of U.S. medical practice based on interviews with leading

experts in the field

-- Qualitative diagnosis/referral/treatment algorithm for the United

States

-- Drug usage by lines of therapy (1st, 2nd, 3rd line)

-- Discussion of key freeform combinations by lines of therapy

-- Product share (class and specific compound level) within each line of

therapy (1st, 2nd, 3rd line)

-- Progression of therapy from key 1st line products

-- Pathway to key therapies from previous therapies

-- Qualitative analysis of 2-year forecast incorporating upcoming

launches, changes in reimbursement, etc.

About Decision Resources

Decision Resources, Inc., (http://www.DecisionResources.com ) is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. DeForest biodiesel plant begins production
2. Biodiesel plant being built in DeForest to make alternative fuel
3. Use of X-rays to advance wood-decay knowledge leads to honor for Forest Products Lab biologist
4. Biodiversity threatened as forests become islands of green, UW professor says
5. BioRobot MDx standardize your automated protocols in clinical laboratories
6. Distance-Learning Remote Laboratories using LabVIEW
7. States are the best laboratories for healthcare reform
8. Scientific Protein Laboratories Acquired by New York firm
9. The Genesis of Gendicine: The Story Behind the First Gene Therapy
10. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
11. TomoTherapy opens technical training center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... May 31, 2016 , ... Adimarket, a ... and approved SVF closed system kit using EmCyte technology, and is expected to be ... to process adipose tissue and obtain stromal vascular fraction (SVF) in a closed environment. ...
(Date:5/31/2016)... ... May 30, 2016 , ... Doctors in Italy say ... live longer than patients with lower levels. Surviving Mesothelioma has just posted an article ... at cancer centers in Genoa and La Spezia, Italy tested the blood serum, tumors, ...
(Date:5/27/2016)... , ... May 27, 2016 , ... PBI-Gordon Corporation is ... and Ornamental Products. , In his 15-year career with PBI-Gordon, Dave has served in ... where he was integral in the development and launch of many of PBI-Gordon’s most ...
(Date:5/26/2016)... and READING, England , ... ( http://www.indegene.com ), a leading global provider of ... pharmaceutical and healthcare organisations and TranScrip ( http://www.transcrip-partners.com ... support throughout the product lifecycle, today announced the ... of IntraScience.      (Logo: http://photos.prnewswire.com/prnh/20141208/720248 ...
Breaking Biology Technology:
(Date:3/31/2016)... BOCA RATON, Florida , March 31, 2016 /PRNewswire/ ... LEGX ) ("LegacyXChange" or the "Company") ... presentation for potential users of its soon to be ... The video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also ... by the use of DNA technology to an industry ...
(Date:3/29/2016)... March 29, 2016 LegacyXChange, Inc. ... "LEGX" and SelectaDNA/CSI Protect are pleased to announce our ... in a variety of writing instruments, ensuring athletes signatures ... created collectibles from athletes on LegacyXChange will be assured ... the DNA. Bill Bollander , CEO ...
(Date:3/22/2016)... 22, 2016 According ... Market for Consumer Industry by Type (Image, Motion, ... (Communication & IT, Entertainment, Home Appliances, & ... to 2022", published by MarketsandMarkets, the market ... reach USD 26.76 Billion by 2022, at ...
Breaking Biology News(10 mins):